Information Provided By: 
Fly News Breaks for March 21, 2017
NVO, GBT
Mar 21, 2017 | 07:34 EDT
Wedbush analyst Liana Moussatos says that Global Blood Therapeutics' (GBT) GBT440 drug can become the standard of care for sickle cell disease, and he thinks that the stock has not risen adequately following speculation that the company had been approached by Novo Nordisk(NVO) about a takeover. The analyst thinks that the company could be acquired for $73-$87 per share, versus its current price of around $37. Target $73.
News For GBT;NVO From the Last 2 Days
